arrow
M

Maria Alessandra Calegari

fondazione policlinico universitario agostino gemelli irccs
H指数:15
被引数:857

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interobserver Agreement and Radiological–Pathological Concordance of CT Staging in localized Colon Cancer

不同观察者间对局部结肠癌CT分期的观察者一致性及影像学-病理学一致性

2026-09-010
OAAI
ASO Visual Abstract: Exploring the Limits of Perigastric Surgery in CRS and HIPEC for Pseudomyxoma Peritonei: A Functional Burden with Preserved Oncologic Outcomes

ASO视觉摘要:探索腹胃周围手术在黏液腺癌腹膜炎中的局限性及HIPEC应用:保留肿瘤学结果的负担功能

2026-05-140
PRE
Treatment-related deaths with immune checkpoint inhibitor–based combinations versus tyrosine kinase inhibitor monotherapy in hepatocellular carcinoma: a systematic review and meta-analysis.

与酪氨酸激酶抑制剂单药治疗相比,免疫检查点抑制剂为基础联合疗法在肝细胞癌中的治疗相关死亡:一项系统评价和荟萃分析

2026-04-300
OAAI
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer

通过NGS进行微卫星不稳定性分析及通过IHC进行错配修复缺陷分析在子宫内膜癌和结直肠癌中的应用

2026-02-250
OAAI
Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data

Clinicomics在预测转移性结直肠癌HER2表达中的应用:一项基于真实世界数据的 multicenter 机器学习分析

2025-12-010
PRE
Long-term survival and prognostic factors after repeated metastasectomies in metastatic colorectal cancer: a 15-years retrospective study

结直肠癌转移患者重复转移灶切除术后的长期生存及预后因素:一项15年回顾性研究

2025-12-010
PRE
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

真实世界证据:regorafenib剂量递增与固定剂量在难治性转移性结直肠癌中的比较:ReTrITA研究的结果

2025-10-140
OAAI
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

pT4N0结肠癌的预后影响与临床管理:来自大型、多中心、国际、真实世界数据集的数据

2025-07-150
OAAI
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
2025-02-010
OAAI
The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC)

多学科肿瘤委员会(MDTB)在结直肠癌(CRC)管理中的影响

2025-01-100
OA
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy
2025-01-070
OAAI
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

阿柏西普为基础和贝伐珠单抗为基础的二线方案在转移性结直肠癌患者中的应用:一项多中心队列研究的倾向性评分加权分析

2025-01-020
OAAI
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance
2024-12-041
OAAI
Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective ReTrITA study

评估接受regorafenib和trifluridine/tipiracil序贯治疗的难治性结直肠癌患者中转移性疾病部位作为预后标志物的价值:多中心回顾性ReTrITA研究的生存结局

2024-09-011
PRE
Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500

同源重组(HR)和DNA损伤修复(DDR)体细胞改变在转移性结直肠癌(mCRC)中的研究:综合基因组分析(CGP)试验FPG500的结果

2024-09-010
PRE